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Learning Objective
• Understand how the initial verification of a lab
instrument can affect the results of a test, and
how it can impact a patient.

Brief outline
• Part 1: Instrument validation and verification.
• Part 2: Local population study, and
establishing new cutoff values.
• Part 3: Look back to determine how new
cutoff values would have affected 1 year of
test results.

Introduction to APAS
• Antiphospholipid antibody syndrome (APAS) is
an autoimmune disorder that is caused by a
person making antibodies to phospholipids
that are found on their own cell membranes.
• Results in an abnormally long aPTT
• Clinical consequences of this can range from
no symptoms to spontaneous venous
thromboembolism (VTE), or spontaneous
pregnancy loss.

Consequences of APAS
• Many people with symptomatic APAS need to
have anticoagulation and/or antiplatelet
therapy for life.
– Increase risk of bleeding

Part 1: The Setup
• TriCore uses the BioPlex platform (Bio-Rad
Laboratories, Hercules, CA) for testing antiphospholipid
antibody syndrome (APAS), which is an FDA approved
test.
• ELISA test for:
– anti-cardiolipin (aCL) IgA, IgG, and IgM
– anti-beta2-glycoprotein 1 (aB2GP1) IgA, IgG, and IgM

• At the time of instillation, Bio-Rad gave a positive cut
off value of 20 U/mL.
• Bio-Rad recommended that cut off values be
established based on a 99th percentile of the local
population.

Where did the 20 U/mL
cutoff value come from?
• FDA validation study
(from the machine
documentation)
• Set-up verification
(available samples)
• It is unclear why the
manufacturer
recommended a cut
off value of 20 U/mL

Table 1: APAS 99th percentiles from
validation and verification studies
Antibody

BioRad
validation
(n=300)

Initial
verification
(n=37)

B2-glycoprotein-1 IgA (U/mL)

12.1

42

B2-glycoprotein-1 IgG (U/Ml)

6

23.8

B2-glycoprotein-1 IgM (U/mL)

19.4

22.9

Anti-cardiolipin IgA
(APL-U/mL)

14.5

45.5

Anti-cardiolipin IgG
(GPL-U/mL)

8.5

27.6

Anti-cardiolipin IgM
(MPL-U/mL)

27.9

19.6

It becomes much less clear.
• There are no international standards in place
for the detection APAS antibodies.
• Different manufacturers use different
monoclonal antibodies for detection.
• Leads to a high degree of variability between
commercially available tests for APAS.
• Increases the importance of establishing a
local population norm for the tests.

Part 2: The study
• Introduction:
• We wanted to establish a local population
cutoff for the APAS tests.
• To do this we proposed collecting 120 samples
from a normal local population.

Methods
• Whole blood samples in sodium citrate were
collected from 120 healthy donors.
• Stored at -70 degrees C for up to 12 months.
• Concentrations of aCL and aB2GP1 were
determined using the BioPlex 2200 System.
• The 99th percentile for each part of the assay
was determined, and implemented as new cut
off value (starting 1/15/2020)

Results
Table. 99th percentile determinations from validation study, verification study and local population study

Antibody

BioRad
validation
(n=300)

Initial
verification
(n=37)

Local
population
(n=120)

B2-glycoprotein-1 IgA
(U/mL)

12.1

42

10.6

B2-glycoprotein-1 IgG
(U/Ml)

6

23.8

6.3

B2-glycoprotein-1 IgM
(U/mL)

19.4

22.9

20.1

Anti-cardiolipin IgA
(APL-U/mL)

14.5

45.5

10

Anti-cardiolipin IgG
GPL-U/mL

8.5

27.6

9.6

Anti-cardiolipin IgM
MPL-U/mL

27.9

19.6

25.9

Part 3: look back for impact
• Newly derived cutoffs were applied to 1,118
aCL and 1,140 aB2GP1 results retrieved from
the TriCore data warehouse over a 12-month
period (1/1/2018 to 12/31/2018).

Results

Results
• Based on our population’s 99th percentile cut-off
values, 27 previously negative individuals would
now be labeled positive, whereas only 3
previously positive individuals would now be
labeled as negative; the majority of patient
results (97.4% of tests) did not change.
• Note: this is a battery of tests, and a result is
dependent on the overall pattern of testing, as
well as a second test at least twelve weeks apart.

Conclusion
• Given guideline recommendations that a local
population be used to establish cut-off values,
TriCore Reference Laboratories have changed the
cut-off values to the 99th percentile of the local
population.
• The 99th percentile results from this study were
similar to those established by Bio-Rad
Laboratories during their validation.
• It is unclear why a uniform value of greater than
or equal to 20 units was applied as the FDAcleared cut-off.

Further work
• It would be interesting to send the samples to
a lab that assays the APAS with a different
method, and compare the results.
• Request IRB approval for evaluate the clinical
significance for the changes in reference
ranges.
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